Prognostic impact of skeletal muscle assessed by computed tomography in patients with acute myeloid leukemia

AbstractSkeletal muscle atrophy and loss of adipose tissue, referred to as sarcopenia and adipopenia, respectively, are often observed in cancer patients. We investigated the impact of sarcopenia and adipopenia on clinical outcomes in 90 adult patients with newly diagnosed acute myeloid leukemia (AML) who received induction chemotherapy. Computed tomography (CT) before treatment revealed sarcopenia in 39 patients (43%) and adipopenia in 35 patients (39%). We analyzed the treatment efficacy of induction chemotherapy and survival outcomes. Three-year overall survival (OS) was 35% in the sarcopenic group and 67% in the non-sarcopenic group (P <  0.001). Three-year OS was 33% in the adipopenic group and 67% in the non-adipopenic group (P <  0.005). Multivariate analysis showed an association between sarcopenia and lower OS (hazard ratio, 2.27; 95% confidence interval, 1.11–4.79;P <  0.05), with other prognostic factors of performance status>  2 (P <  0.05) and adverse cytogenetic risk (P <  0.05). In elderly patients over 60 years old, 3-year OS was 0% for the sarcopenic group and 49% for the non-sarcopenic group (P <  0.0005). These results indicate the prognostic values of sarcopenia in adult patients with AML.
Source: Annals of Hematology - Category: Hematology Source Type: research